Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients

[1]  Tore Wentzel-Larsen,et al.  Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. , 2016, Clinical nutrition.

[2]  A. Weaver,et al.  Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. , 2016, Gynecologic oncology.

[3]  Haa-Na Song,et al.  Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone , 2016, Journal of cachexia, sarcopenia and muscle.

[4]  J. Soria,et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.

[5]  T. Pawlik,et al.  Role of frailty and sarcopenia in predicting outcomes among patients undergoing gastrointestinal surgery. , 2016, World journal of gastrointestinal surgery.

[6]  M. Sawyer,et al.  Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens , 2016, Cancer medicine.

[7]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[8]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[9]  J. Larkin,et al.  The cost of ipilimumab toxicity: a single-centre analysis , 2015, Melanoma research.

[10]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[11]  S. Parsons,et al.  Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  J. W. Kim,et al.  Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy , 2015, Supportive Care in Cancer.

[13]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[14]  Julien Taieb,et al.  Sarcopenia Is Linked to Treatment Toxicity in Patients With Metastatic Colorectal Cancer , 2014, Nutrition and cancer.

[15]  L. Mccargar,et al.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  V. Baracos,et al.  Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. , 2013, The Journal of clinical endocrinology and metabolism.

[17]  O. Mir,et al.  Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients , 2013, British Journal of Cancer.

[18]  O. Mir,et al.  Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma , 2012, PloS one.

[19]  Michael J. Englesbe,et al.  Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma , 2011, Annals of Surgical Oncology.

[20]  L. Birdsell,et al.  Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Tony Reiman,et al.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[22]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[23]  S. Steinberg,et al.  Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade , 2007, Clinical Cancer Research.

[24]  Tony Reiman,et al.  Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity , 2007, Clinical Cancer Research.